Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer

Published:December 13, 2014DOI:


      The purpose of this study was to compare clinical characteristics and survival between patients with stage I epithelial ovarian cancer and fallopian tube cancer.

      Study Design

      We identified women with stage I epithelial ovarian cancer and fallopian tube cancer who underwent treatment from 2000-2010. Correlation between categoric variables was assessed with χ2 test. The Kaplan-Meier survival analysis was used to generate overall survival data. Factors predictive of outcome were compared with the use of the log-rank test and Cox proportional hazards model.


      The study group consisted of 385 women with epithelial ovarian cancer and 43 women with fallopian tube cancer. Patients with fallopian tube cancer had a higher rate of stage IA disease (65% vs 48%; P = .02) and grade 3 tumors (60.4% vs 30.9%; P < .001). Patients with fallopian tube cancer had a significantly higher rate of breast cancer (25.6% vs 5.7%; P < .001) and BRCA 1 mutations (45.8% vs 9.1%; P < .001). There was no difference in the rates of platinum-based and paclitaxel chemotherapy between the groups. Women with fallopian tube cancer were more likely to have received ≥6 cycles of chemotherapy (58.1% vs 44.1%; P = .02). The 5-year disease-free survival rates were 100% in women with fallopian tube cancer and 93% in patients with epithelial ovarian cancer (P = .04). The 5-year overall survival rates were 100% and 95% for fallopian tube cancer and epithelial ovarian cancer, respectively (P = .7).


      We found a higher rate of stage IA, grade 3, and serous carcinoma in fallopian tube cancer. Women with fallopian tube cancer had a higher rate of breast cancer. There was no difference in overall survival between the groups.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cannistra S.A.
        Cancer of the ovary.
        N Engl J Med. 2004; 351: 2519-2529
        • Hennessy B.T.
        • Coleman R.L.
        • Markman M.
        Ovarian cancer.
        Lancet. 2009; 374: 1371-1382
        • Elit L.
        • Chambers A.
        • Fyles A.
        • Covens A.
        • Carey M.
        • Fung M.F.
        Systematic review of adjuvant care for women with stage I ovarian carcinoma.
        Cancer. 2004; 101: 1926-1935
        • Pectasides D.
        • Pectasides E.
        • Economopoulos T.
        Fallopian tube carcinoma: a review.
        The Oncologist. 2006; 11: 902-912
        • Wethington S.L.
        • Herzog T.J.
        • Seshan V.E.
        • et al.
        Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.
        Cancer. 2008; 113: 3298-3306
        • International Federation of Gynecology and Obstetrics
        Changing in definitions of clinical staging for carcinoma of the cervix and ovary.
        Am J Obstet Gynecol. 1987; 156: 263-264
        • Rauh-Hain J.A.
        • Diver E.J.
        • Clemmer J.T.
        • et al.
        Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
        Gynecol Oncol. 2013; 131: 46-51
        • Tognon G.
        • Carnazza M.
        • Ragnoli M.
        • et al.
        Prognostic factors in early-stage ovarian cancer.
        Ecancermedicalscience. 2013; 13: 325
        • Chan J.K.
        • Tian C.
        • Monk B.J.
        • Herzog T.
        • Kapp D.S.
        • Bell J.
        Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
        Cancer. 2008; 112: 2202-2210
        • Moore K.N.
        • Moxley K.M.
        • Fader A.N.
        • et al.
        Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
        Gynecol Oncol. 2007; 107: 398-403
        • Vaysse C.
        • Touboul C.
        • Filleron T.
        • et al.
        Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.
        J Gynecol Oncol. 2011; 22: 9-17
        • Young R.C.
        • Walton L.A.
        • Ellenberg S.S.
        • et al.
        Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials.
        N Engl J Med. 1990; 322: 1021-1027
        • International Collaborative Ovarian Neoplasm (ICON1) and European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant Chemotherapy in Ovarian Neoplasm (EORTC-ACTION)
        International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
        J Natl Cancer Inst. 2003; 95: 105-112
        • Bell J.
        • Brady M.F.
        • Young R.C.
        • et al.
        Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
        Gynecol Oncol. 2006; 102: 432-439
        • Folkins A.K.
        • Jarboe E.A.
        • Roh M.H.
        • Crum C.P.
        Precursors to pelvic serous carcinoma and their clinical implications.
        Gynecol Oncol. 2009; 113: 391-396
        • Winter-Roach B.A.
        • Kitchener H.C.
        • Lawrie T.A.
        Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
        Cochrane Database Syst Rev. 2012; 3: CD004706
        • Trimbos B.
        • Timmers P.
        • Pecorelli S.
        • et al.
        Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.
        J Natl Cancer Inst. 2010; 102: 982-987
        • Elit L.
        • Chambers A.
        • Fyles A.
        • Covens A.
        • Carey M.
        • Fung M.F.
        Systematic reviews of adjuvant care for women with stage I ovarian carcinoma.
        Cancer. 2004; 101: 1926-1935
        • Levine D.A.
        • Argenta P.A.
        • Yee C.J.
        • et al.
        Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
        J Clin Oncol. 2003; 21: 4222-4227
        • Stewart S.L.
        • Wike J.M.
        • Foster S.L.
        • Michaud F.
        The incidence of primary fallopian tube cancer in the United States.
        Gynecol Oncol. 2007; 107: 392-397
        • Vicus D.
        • Finch A.
        • Cass I.
        • et al.
        Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
        Gynecol Oncol. 2010; 118: 299-302
        • Rauh-Hain J.A.
        • Nitschmann C.C.
        • Worley M.J.
        • et al.
        Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
        Gynecol Oncol. 2013; 129: 63-68